Friday, November 12, 2021 1:12:07 AM
I have met a number of people in my career that work harder at trying to cover up that they are not working than it would be to actually do the work. So when I hear someone say, I have been working really hard, I generally ask “at what.” Hard work does not mean meaningful contribution or equate to results.
If they continue to be working hard on the paper, we got real problems because that means it hasn’t been submitted yet. After the submission, the hard work is watching paint dry for a few months before you get comments back, and by the way those comments are sent to LL, not NWBO. Then there are adjustments and response before watching paint dry again. After submission, not much work to be done really.
Since it is a BLA submission that leads to revenue generation, most companies make that the priority and publication takes a back seat. Besides, the data for most companies has already been presented in Congress so why rush to get the publication out when there are more pressing issues like delivering drug to patients and profit for shareholders. You can reference Congress presentations in your marketing materials because it is peer reviewed data. Publications generally follow approval by a few to several months. But we have been told that publication is our number one priority and they are working very hard on the process outlined on October 5th, 2020. I assume we have been working on the BLA submission in parallel.
Here is to hoping that despite not being told the BLA submission is a priority, that it actually is a priority. It is wishful thinking since most companies, even the small one, would have their BLA submitted within a year of locking the database. Most of them closer to six months afterwards.
We deserve to know more about what is going on at NWBO than at Advent, but we don’t. We know quite a bit about what Advent has been doing, which isn’t necessarily to support our business.
I have faith that a BLA is in the works and that data is positive, but I recognize that at this point those two comments are faith. I was angry, but now I am sad because I tried to think about what it must be like to watch these events while having had surgery for GBM and going through chemo/rad hoping your tissue can be made in to DCVax some day soon. I live in America, so waiting would be my only option.
I am truly sad for all of those people. This must really, really suck and hope must be quite low for them.
If they continue to be working hard on the paper, we got real problems because that means it hasn’t been submitted yet. After the submission, the hard work is watching paint dry for a few months before you get comments back, and by the way those comments are sent to LL, not NWBO. Then there are adjustments and response before watching paint dry again. After submission, not much work to be done really.
Since it is a BLA submission that leads to revenue generation, most companies make that the priority and publication takes a back seat. Besides, the data for most companies has already been presented in Congress so why rush to get the publication out when there are more pressing issues like delivering drug to patients and profit for shareholders. You can reference Congress presentations in your marketing materials because it is peer reviewed data. Publications generally follow approval by a few to several months. But we have been told that publication is our number one priority and they are working very hard on the process outlined on October 5th, 2020. I assume we have been working on the BLA submission in parallel.
Here is to hoping that despite not being told the BLA submission is a priority, that it actually is a priority. It is wishful thinking since most companies, even the small one, would have their BLA submitted within a year of locking the database. Most of them closer to six months afterwards.
We deserve to know more about what is going on at NWBO than at Advent, but we don’t. We know quite a bit about what Advent has been doing, which isn’t necessarily to support our business.
I have faith that a BLA is in the works and that data is positive, but I recognize that at this point those two comments are faith. I was angry, but now I am sad because I tried to think about what it must be like to watch these events while having had surgery for GBM and going through chemo/rad hoping your tissue can be made in to DCVax some day soon. I live in America, so waiting would be my only option.
I am truly sad for all of those people. This must really, really suck and hope must be quite low for them.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
